ScienceRise: Biological Science https://journals.uran.ua/sr_bio <p>«ScienceRise: Biological Science» – scientific peer-reviewed journal, published 4 times a year, included in category “B” «List of scientific professional editions of Ukraine» for specialty 091-Biology (Сertificated by order of Ministry of Education and Science of Ukraine No. 612 from 07.05.2019) and for specialty 211- Veterinary medicine (Сertificated by order of Ministry of Education and Science of Ukraine No. 320 from 07.04.2022).</p> <p>Registration of an entity in the media sector: Decision of the National Council of Ukraine on Television and Radio Broadcasting No. 695 dated August 10, 2023, protocol No. 17 (media identifier R30-01133).</p> <p style="font-weight: 400;">The goal of "ScienceRise: Biological Science" journal is to provide a platform for scientists to share scientific data in all aspects of the life sciences.</p> <p style="font-weight: 400;">The concept of "Ecosystems", which is considered from three points of view, is at the center of the researched issues of the journal:</p> <p style="font-weight: 400;">– biota, which is affected by external factors caused by human activity,<br />– the influence of environmental factors on the health of people and animals,<br />– medicinal properties of plants for their use in medicinal preparations.</p> <p style="font-weight: 400;">Such a focus of research should cover applied aspects related to human and animal health: identification of the causes of diseases and diagnosis based on microbiological studies, prevention, effects of medicinal drugs and supplements, biotechnological solutions for improving the state of health care and the environment.</p> <p style="font-weight: 400;">Therefore, the areas of scientific research covered in the "ScienceRise: Biological Science" journal are divided as follows:</p> <p style="font-weight: 400;">Life Sciences:</p> <ul> <li style="font-weight: 400;">Biological and agricultural sciences (plants that have medicinal properties);</li> <li style="font-weight: 400;">Biochemistry, genetics and molecular biology (biochemistry, biotechnology);</li> <li style="font-weight: 400;">Environmental science (ecology, health, toxicology and mutagenesis);</li> <li style="font-weight: 400;">Immunology and microbiology (applied microbiology and biotechnology, immunology, parasitology, virology).</li> </ul> <p style="font-weight: 400;">Health Sciences</p> <ul> <li style="font-weight: 400;">Pharmacology, toxicology and pharmaceuticals;</li> <li style="font-weight: 400;">Veterinary and veterinary medicine.</li> </ul> <p><a href="https://portal.issn.org/resource/ISSN/2519-8017">ISSN 2519-8017</a>, <a href="https://portal.issn.org/resource/ISSN/2519-8025ISSN">E-ISSN 2519-8025</a>, <a href="https://portal.issn.org/resource/ISSN/2519-8017">ISSN-L 2519-8017</a><br /><br />Drawing up the items of the publication ethics policy of the journal «ScienceRise: Biological Science» Editors followed the recommendations of Committee on Publication Ethics<a href="http://publicationethics.org/"> (COPE)</a>.</p> ТЕСHNOLOGY СЕNTЕR PC en-US ScienceRise: Biological Science 2519-8017 <p>Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.</p> <p>Authors, who are published in this journal, agree to the following conditions:</p> <p>1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.</p> <p> 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.</p> The effect of caffeine on alpha activity in the cerebral cortex of rats in different models of depression https://journals.uran.ua/sr_bio/article/view/325272 <p><strong>The aim of the study</strong> is to determine changes in the power spectral density of the alpha-like rhythm of the cerebral cortex in models of contagious depression and chronic unpredictable stress, as well as to study the effect of caffeine on these indicators.</p> <p><strong>Materials and methods</strong>. The study was conducted on white sexually mature male rats weighing 230–300 grams. Six groups were formed according to the type of depression and caffeine consumption. The electroencephalographic method was used, and the power spectral density analysis in the alpha range was performed to assess the depressive-like state and the effect of caffeine. The power spectral density of alpha activity (8–12 Hz) was assessed in the cortical zones of male rats: Fp1, Fp2, F3, F4, P3, P4, O1, O2.</p> <p><strong>Results.</strong> The assessment of the power spectral density of activity in the 8–12 Hz range in the Fp1 and Fp2 points showed a statistically significant interaction between the type of depression and the effect of caffeine. In the Fp2 area, the effect of depression was more noticeable. In both types of depression, a significant increase in the power spectral density in the 8–12 Hz range was observed in the F3 and F4 areas. The administration of caffeine reduced these indicators, but did not ultimately reduce the effects of depression. In the P3 and P4 points, depression has no significant impact on the power spectral density, while caffeine reduces the power of the alpha range in both hemispheres. Caffeine reduced the power spectral density in all groups in the occipital areas (points O1 and O2). In contrast, in animals with depressive states, the effect of caffeine was only partial.</p> <p><strong>Conclusions.</strong> Depression of different genesis affects different parts of the brain differently. Alpha spectral power density increases in frontal and occipital regions and decreases in the prefrontal cortex. Caffeine significantly reduces power spectral density in occipital, frontal, and parietal areas</p> Valeriia Mizin Olena Severynovska Copyright (c) 2025 Valeriia Mizin, Олена Вікторівна Севериновська http://creativecommons.org/licenses/by/4.0 2025-04-10 2025-04-10 1 (42) 4 11 10.15587/2519-8025.2025.325272 Antimycobacterial activity of new aryloxyethoxy-dialkylaminopropanol derivatives against reference strains of nontuberculous mycobacteria https://journals.uran.ua/sr_bio/article/view/326435 <p><strong>Objective. </strong>To evaluate the in vitro antimycobacterial activity of novel quaternary ammonium salts, derived from alkyl(aryloxyethoxy)dialkylaminopropanol against reference strains of nontuberculous mycobacteria (NTM).</p> <p><strong>Materials and Methods. </strong>A total of 52 synthesized compounds, obtained via phase-transfer catalysis, were studied,. The activity was assessed in two stages: initial screening using the agar diffusion method (well method), followed by minimum inhibitory concentration (MIC) determination through serial dilution. Primary testing was performed on Mycobacterium smegmatis, followed by evaluation on M. terrae, M. avium, and M. B5 using the proportion method on Löwenstein–Jensen medium. Compounds were tested at three concentrations: K-I (MIC for M. smegmatis), K-II (10×MIC), and K-III (100×MIC).</p> <p><strong>Results. </strong>Ten compounds with the highest activity against M. smegmatis were identified during the screening stage. The most active was Kc12 (MIC – 0.22±0.02 µg/mL). Other active compounds included: Kc16, Kc13, Kc15, Kp15, Kp20, Kp18, Kc22, Kc14, and Kp16. Among the NTM strains, M. terrae and M. B5 were the most sensitive. At K-II, compounds Kc12, Kc13, Kc15, Kc16, Kc22, and Kp18 inhibited bacterial growth by more than 95 %. Kc15 demonstrated the efficacy comparable to rifampicin, while Kp18 and Kc12 surpassed streptomycin. M. avium exhibited resistance, with growth suppression below 5 %, observed only at K-III in a few compounds. The least active was Kp20.</p> <p><strong>Conclusions. </strong>Ten promising compounds were identified, notably Kc12, Kc15, Kp18, Kc16, and Kc22, whose activity exceeded that of streptomycin and approached rifampicin in some cases. The findings highlight the potential of these compounds for further preclinical development in the treatment of NTM infections</p> Volodymyr Nastenko Copyright (c) 2025 Volodymyr Nastenko http://creativecommons.org/licenses/by/4.0 2025-04-10 2025-04-10 1 (42) 12 17 10.15587/2519-8025.2025.326435